Kyong-Hoon Ahn

Title: **Kyong-Hoon Ahn: Innovator in Albumin Binding Polypeptides**

Introduction

Kyong-Hoon Ahn is a distinguished inventor based in Seoul, South Korea. He has made significant contributions to the field of biochemistry, notably through his innovative research on engineered polypeptides. His work focuses on improving the properties and applications of these molecules, particularly in medical science.

Latest Patents

Kyong-Hoon Ahn holds a patent for an albumin binding polypeptide, which is a groundbreaking innovation. This patent details a class of engineered polypeptides that exhibit a strong binding affinity for albumin, designed to have high resistance to enzymatic cleavage. The invention includes an albumin binding polypeptide characterized by the specific amino acid sequence: GVSDFYKKLI XKAKTVEGVE ALKXXI (SEQ ID NO:29). This advancement could have significant implications in therapeutic applications, enhancing drug delivery systems.

Career Highlights

Currently, Kyong-Hoon Ahn is employed at Affibody AB, a company known for its pioneering work in biopharmaceuticals and protein engineering. His research is critical in pushing the boundaries of how therapeutic proteins interact with human biology, signifying his role as an innovator in his field.

Collaborations

Throughout his career, Kyong-Hoon Ahn has worked alongside talented individuals, including his coworkers Caroline Ekblad and Joachim Feldwisch. Collaborating with experts in the field has enriched his research and contributed to the development of his patent.

Conclusion

Kyong-Hoon Ahn's contributions to the development of albumin binding polypeptides highlight the importance of innovation in biochemistry. His work at Affibody AB, combined with his ability to collaborate with other experts, positions him as a key figure in the ongoing advancement of therapeutic proteins, showcasing the potential of engineered polypeptides in medical applications.